InspireMD, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023; filed March 5, 2024. This is an annual filing, and the supplied text does not provide standalone fourth-quarter results.
Business context
InspireMD develops and sells medical devices based on its MicroNet mesh technology. Its primary commercial product is CGuard EPS, a mesh-covered carotid stent sold through international distributors. The company is developing CGuard Prime for potential U.S. commercialization and SwitchGuard, a neuroprotection system for transcarotid procedures. CGuard is not FDA-approved for commercial sale in the United States.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $6.205 million | $5.171 million |
| Gross profit / margin | $1.807 million / 29.1% | $1.117 million / 21.6% |
| Operating expenses | $22.950 million | $19.830 million |
| Operating loss | $21.143 million | $18.713 million |
| Net loss | $19.916 million | $18.491 million |
| Net cash used in operations | $16.376 million | $15.542 million |
Revenue rose 20.0%, primarily from higher CGuard sales in existing and new markets. Gross margin improved, with management citing increased sales and lower inventory write-offs. Operating expenses rose 15.7%, notably due to higher general and administrative costs, including share-based compensation and personnel expenses. Higher financial income partly offset the wider operating loss.
At year-end, cash and cash equivalents were $9.640 million and marketable securities were $29.383 million, versus cash of $4.632 million and short-term bank deposits of $13.171 million in 2022. Working capital was $38.139 million. Current assets exceeded current liabilities 7.3 times. No interest-bearing borrowings are reported in the balance sheet; liabilities include operating lease obligations and employee-related liabilities. Lease payments total approximately $1.816 million, scheduled through 2026.
The May 2023 private placement generated $42.2 million in gross proceeds and approximately $37.5 million net proceeds after issuance costs. Management said available resources could fund planned operations for at least 12 months from issuance of the financial statements, while also warning that additional capital may be needed.
Material developments and outlook
- C-GUARDIANS completed enrollment of 316 patients at 24 U.S. and European sites in June 2023. Reported 30-day DSMI rates were 0.95% in the intent-to-treat analysis and 0.63% per protocol. The one-year primary endpoint remained pending.
- Management expected to report primary endpoint results in mid-2024, potentially submit a PMA in the third quarter of 2024, and pursue possible FDA approval in the first half of 2025. These are targets, not assured outcomes.
- CGuard EPS received EU MDR CE-mark recertification in January 2024. CMS expanded U.S. carotid stenting coverage in October 2023 to include asymptomatic and standard-risk patients.
- The company plans an IDE submission for the SwitchGuard C-GUARDIANS II study in the second half of 2024. A 15-patient early feasibility study of CGuard for acute stroke patients with tandem lesions was also planned, with first enrollment expected in the second quarter of 2024.
- In 2022 the company ceased MGuard Prime sales after demand shifted toward drug-eluting stents; 2023 revenue was entirely from CGuard EPS.
Risks, contingencies, and unusual items
- Recurring losses and operating cash outflows persist. The company reported an accumulated deficit of $221.5 million at year-end and expects further losses; profitability is not established.
- Potential dilution is substantial: at December 31, 2023, 53.4 million common-share warrants and 15.3 million pre-funded warrants were outstanding. Full cash exercise of the 2023 warrants could generate $71.4 million, but exercise is uncertain and subject to terms and milestones. The company reported 23.46 million common shares outstanding on March 5, 2024.
- Manufacturing is concentrated at the Tel Aviv facility. The company disclosed that its polymer-fiber supplier cannot supply the material in the future and that it is validating an alternative. The filing gives differing inventory coverage estimates—through the end of 2026 in one section and through mid-2028 in another.
- The Israel-Hamas war had not materially disrupted operations through the filing date, but the facility and key personnel are in Israel and commercial insurance excludes war- and terrorism-related losses. Russia and Belarus accounted for approximately 13.5% of 2023 sales; sanctions and collection difficulties are cited as risks.
- Other key risks include clinical or regulatory delays or failure, reimbursement and market adoption, competition, supplier interruption, foreign-exchange exposure, and the need for future financing. No pending material legal proceedings were reported.
- Management reported effective disclosure controls and internal control over financial reporting as of December 31, 2023. The independent auditor issued an unqualified opinion on the financial statements and reported no critical audit matters.
Investor facts to verify
- Review the eventual one-year C-GUARDIANS results and whether they meet the prespecified endpoint and support a PMA filing.
- Track actual FDA and IDE milestones, including SwitchGuard study plans, against management’s stated timelines.
- Assess cash burn and funding runway against the company’s commercialization and development spending plans.
- Confirm the status and potential dilution from outstanding warrants and pre-funded warrants, including actual exercise proceeds.
- Clarify the polymer-fiber inventory coverage discrepancy and progress in validating the replacement source.
- Monitor Israel-related operating exposure and Russia/Belarus sales, collections, and sanctions impacts.